+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Neurophysins in Central Diabetes insipidus

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          When they were discovered by Acher and co-workers, neurophysins were thought to act as carriers for the active nonapeptides vasopressin (AVP) and oxytocin (OT) and were then recognized as the inactive fragment of a precursor with a higher molecular weight (propressophysin). The role of neurophysins in the hypothalamo-neurohypophyseal system is now being reconsidered in the light of crystallographic and molecular biology research and the recent definition of the different deletions or substitutions that cause central diabetes insipidus in rats (Brattleboro) or human beings. Apparently, any disruption of the strucuture and/or conformation of neurophysins (by genie substitution or deletion) may cause a decline in the binding and the activity of the endopeptidase responsible for the cleavage of the AVP. The disruption may also produce a change in the polymerization of neurophysins and salt bridges relating this to the neuropeptides, with the result that there is an accelerated aspecific enzymatic degradation of the hormone revealing clinical symptomatology. So, rather than being a mere inactive part of the precursor, neurophysins are now equally regarded as a system for carrying and protecting nonapeptides.

          Related collections

          Author and article information

          Horm Res Paediatr
          Hormone Research in Paediatrics
          S. Karger AG
          09 December 2008
          : 45
          : 3-5
          : 182-186
          Endocrinology Department, Centre Hospitalier Universitaire-Sart Tilman, Liège, Belgium
          184784 Horm Res 1996;45:182–186
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Hormone Binding Proteins: Physiology and Clinical Implications


          Comment on this article